In the group of patients with PD-L1 expression on at least 50% of tumour cells, a median OS was not reached (95% CI: 17.9–NR) within cemiplimab treatment, but it was 14.2 months (95 CI: 11.2–17.5) in patients receiving platinum-based chemotherapy. This evidence concerns the gene CD274 and neoplasm.